Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07652658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Study acronym: ARGiNAUT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 190 → 195 locations Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 1 of 7 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 7 entries
  2. Recruitment opened Primary and study completion dates: Sep 18, 2028 to Sep 14, 2028 · Start date changed from estimate of Jun 15, 2026 to Jun 11, 2026 · Site details revised at 190 of 190 sitesv2 Show 3 more changesShow less
    • Primary and study completion dates: Sep 18, 2028 to Sep 14, 2028
    • Start date changed from estimate of Jun 15, 2026 to Jun 11, 2026
    • Site details revised at 190 of 190 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Trial Details
NCT Number NCT07652658
Lead Sponsor AstraZeneca
Conditions Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 359 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov